ASX BRIEFS

INVION LTD (IVX) - From Lab To Clinic: How Invion’s Light-Activated Therapy Targets Cancer And Infections

• Andrew Musgrave

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 11:47

Send us Fan Mail

What if a beam of light could turn the tide against stubborn tumours and even wake the immune system? We sit down with Professor Thian Chew, Executive Chair and CEO of Invion Limited, to unpack how their photodynamic therapy zeroes in on cancer cells, stays inert until activated by a specific wavelength, and then triggers targeted oxidation that spares healthy tissue. The kicker: this same mechanism appears to amplify immune responses and shows promise against infectious agents like bacteria, fungi, and viruses.

We walk through concrete progress already underway. A non‑melanoma skin cancer study advances a topical application, while a forthcoming anogenital cancer trial with the Peter MacCallum Cancer Centre explores combining light‑activated therapy with established immunotherapies to convert “cold” tumours into “hot” responders. Backing from South Korea’s KDDF and partner Hanlim Pharma brings up to two million dollars in non‑dilutive support focused on oesophageal cancer and the development of an IV formulation. With both topical and IV routes, the platform can map to diverse clinical settings and multiple tumour types.

A major strategic shift came with Invion’s perpetual, exclusive global licence to the Photosoft™ platform. That move removes a long‑standing overhang, giving us the freedom to set indication priorities, simplify global partnerships, and negotiate clean commercial pathways. Under the hood, the science uses glucose conjugates to exploit the Warburg effect, letting sugar‑hungry tumours absorb the compound across a range of cancers. Beyond human oncology, our partnership with Protect Animal Health pushes a parallel pet oncology program that can reach companion animal trials faster, potentially generating earlier revenue and translational insights.

We close with a clear look at the next 12–18 months: continued recruitment and readouts in skin cancer, regulatory steps and initiation milestones with Peter Mac, preclinical efficacy and formulation updates in oesophageal cancer, and progress across companion animal studies. With recent capital raised and R&D facilities in place, plus non‑dilutive partner funding, the runway supports a steady cadence of data. If you’re tracking precision oncology, immune priming, and platform therapeutics, this is a roadmap worth following.

Enjoyed the conversation? Subscribe, share with a friend who follows biotech, and leave a quick review to tell us which upcoming catalyst you’re watching most.